Congrats for this outstanding achievement . You are awesome !!!

Check out #ASCO24 highlights by high5md high5oncology.tv/meeting-covera… Faculty Hans Hammers joaquim bellmunt Anders Bjartell Simon C Ignacio Duran Eleni Efstathiou Peter J. Goebell Marc-Oliver Grimm Petros Grivas ylt Axel S. Merseburger Alicia Morgans, MD, MPH Declan Murphy Tom Powles Brian Rini, MD Sumanta K. Pal, MD, FASCO

🟡First immunotherapy regimen before and after surgery to extend survival in bladder cancer 🟡Happy to be part of NIAGARA trial! Tom Powles OncoAlert astrazeneca.com/media-centre/p…

JUST IN: Durvalumab extends EFS and OS In muscle-invasive bladder cancer —major news with IO moving earlier stages in balder cancer ! OncoAlert Oncology Times Oncology Brothers Tom Powles Targeted Oncology OncLive.com astrazeneca.com/media-centre/p…

What team can really beat Spain 🇪🇸 in #EURO2024 ? The stats says it all…what an impressive dominance so far and impressive squad depth!

CHMP gives a positive recommendation for Enfortumab Vedotin and Pembrolizumab in 1st line advanced UC. Paving the way for use in Europe. merck.com/news/merck-rec…

Positive EU Opinion for PD1 ing Pembro + ADC EV as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Cancer ! ⁦Dana-Farber Lank Center for Genitourinary Oncology⁩ ⁦Tom Powles⁩ ⁦joaquim bellmunt⁩ ⁦⁦Bradley McGregor⁩ merck.com/news/merck-rec…

Chowdhury Lab UT Health San Antonio National Cancer Institute Wonderful work Dipanjan and team. Toni Choueiri, MD Neeraj Agarwal, MD, FASCO Adam Sharp Alex Wyatt Arun Azad Elena Castro joaquim bellmunt

💫Proud of learning from negative trials. “Induction avelumab followed by chemoimmunotherapy and maintenance vs chemo alone as f1st line therapy in cis-ineligible mUC (INDUCOMAIN): a randomized phase II study” is out⚡️#rodriguez-vida Bego PValderrama SOGUG Dana-Farber Lank Center for Genitourinary Oncology Dana-Farber

Patient Preferences for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma. What is most important to patients regarding their experiences of disease burden and treatment #BladderCancer ⁦Nicholas Simon⁩ link.springer.com/article/10.100…

🔝🔝🔝🎓Beautiful article, you must read it!! 💫🌟🔍 INDUCOMAIN Study: Evaluation of avelumab plus chemotherapy in cisplatin-ineligible metastatic urothelial carcinoma.🌟💫 Bego PValderrama Daniel Castellano Álvaro Pinto Javier Puente, Dr. E. Gonzalez-Billalabeitia, joaquim bellmunt. SOGUG

How it started. How it’s going😉 Thank you incredible mentors Eli Van Allen and Kent Mouw, role models surgeon-scientists Dr. E Mittendorf Chris Barbieri, collaborators Michelle_Hirsch (Donovan) Jennifer Guerriero, PhD joaquim bellmunt, our BWH comp urology group, my wife Filipa Lynce, MD, FASCO, fam and friends

Should Enfortumab Vedotin with Pembrolizumab be avoided due to baseline clinical conditions? Sometimes, but clinical judgement is more important than predefined criteria Andrea Apolo, M.D. Shilpa Gupta joaquim bellmunt Jonathan Rosenberg MD Michiel van der Heijden & Lisa Cordes gbr01.safelinks.protection.outlook.com/?url=https%3A%…

💫Interesting data to confirm in a clinical trial;Our article "Enhancing IO-therapy through PD-L1 upregulation: the promising combination of anti-PD-L1 + mTOR inhibitors" online @ Mol. Onc. Expanding the role of mTORC1/2 inhibitor sapanisertib (TAK-228) OncoAlert Dana-Farber Lank Center for Genitourinary Oncology

Congrats joaquim bellmunt & your team Dana-Farber Lank Center for Genitourinary Oncology Dana-Farber

Exciting data on advanced urothelial carcinoma! Promising results from the EGFR x HER3 bispecific ADC and practice-changing trials like NIAGARA will shape the future of bladder cancer treatment. Stay tuned for more at #ESMO24 #cancer #oncology @oncoalert ESMO - Eur. Oncology World Bladder Cancer Patient Coalition

Brilliant presentation by Andrea Apolo, M.D. with extended 45 mo f/u from the #AMBASSADOR trial #ESMO2024 Adjuvant pembro in high risk MIBC: consistent DFS benefit regardless of PD-L1 and LN status Now in NEJM ESMO - Eur. Oncology OncoAlert

Up now - DAD update for #ESMO24! With 22 month followup SG+EV for 2L+ active with no new toxicity signals. ORR 70% with 4 CR; 6 patients with ongoing response - median DOR 10 months (range 3-33+). DADIO coming soon! joaquim bellmunt Toni Choueiri, MD Dana-Farber Lank Center for Genitourinary Oncology

Beautiful discussion (as usual!) by Shilpa Gupta Cleveland Clinic. Wonderful background, context & practical implications for #HOG study evaluating #nivolumab in #TMT in #bladdercancer provided through citations of studies by Arjun Balar MD Minas Economides, MD Parminder singh

👍Remembering old times. Getting together at ESMO 2024 in Barcelona after a long time of having been together💫✨. ESMO - Eur. Oncology #ValleHebron #ESMO2024 Dana-Farber Lank Center for Genitourinary Oncology Hospital del Mar